Other News Releases in Health Care & Hospitals
Congressman Fattah: Thanks to Specter, Casey for a Major Step Along History's Path
Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure
Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill
Other News Releases in Trade Show News
River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries
U.S.-China Business Summit to Host World's Largest Symposium for Americans, Chinese
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News
Trubion Announces Upcoming Presentation at 8th Annual BIO Investor Forum
SEATTLE, Oct. 26 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced it will present a corporate update at the upcoming 8th Annual BIO Investor Forum to be held at the Palace Hotel in San Francisco. Dr. Peter Thompson, FACP, president, chief executive officer and chairman of the board of directors, is scheduled to present in the Pacific Heights room on Thursday, Oct. 29 at 1:30 p.m. PDT. The presentation will be available via audio webcast at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=TRBN&item_id=2478554.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)
About Trubion
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Pfizer collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the company's Facet Biotech collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules like CD79b and HLA-DR, as well simultaneously neutralizing soluble ligands like TNF and IL-6. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.
TRBN-G
Contact:
Jim DeNike
Senior Director, Corporate Communications
Trubion Pharmaceuticals, Inc.
(206) 838-0500
jdenike@trubion.com
http://www.trubion.com
Waggener Edstrom Worldwide Healthcare
Amy Petty
Senior Account Executive
(617) 576-5788
amyp@waggeneredstrom.com
SOURCE Trubion Pharmaceuticals, Inc.